psoriasis

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
A new class steps forwardPhosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).
TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
Psoriasis and skin cancerCyclosporine and PUVA clearly increase the risk of squamous cell carcinomas, and there is evidence that TNF blockers and methotrexate may do so to a lesser degree. UVB phototherapy has not been shown to cause skin cancer. Acitretin offers protection against the development of basal cell and squamous cell carcinomas.
9 Newly Approved Novel Drugs
9 Newly Approved Novel DrugsIt's still early in 2017, but the FDA has been approving drugs left and right. Here's what you need to know.
Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Psoriasis underdiagnosed, undertreatedIn skin of color, psoriasis can be tough to spot, and it carries a broader differential diagnosis. Darker-skinned patients may not know that they can develop psoriasis, or the importance of seeking treatment early.
Research gaps persist in psoriasis, psoriatic arthritisBeing able to predict which patients will respond to which treatments will help dermatologists in treating psoriasis, preventing progression to psoriatic arthritis and reducing comorbidities.
Genetic insights inform autoinflammatory therapiesKnowing the genetic basis of monogenic skin diseases may one day help dermatologists treat non-monogenic skin diseases as well.
Psoriasis drug approved with boxed warningA new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.